Abbott Laboratories said it could resume infant formula production within two weeks at a Michigan manufacturing plant that has been shut since February because of bacterial contamination concerns, exacerbating a nationwide formula shortage.

The Illinois-based company said Wednesday it would resume production pending approval from the Food and Drug Administration, which has been conducting an investigation into whether bacterial contamination at the plant caused the illnesses of four babies, two of whom died, after being fed Abbott-brand formula. The babies were infected by a bacteria called cronobacter sakazakii, which is known to survive in dry foods such as infant formula powder.

To Read the Full Story

This post first appeared on wsj.com

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

What does it take to make a hip-hop hit? TikTok.

The Chorus It’s been a year since White was signed to Def…

Ex-Spanish soccer president Luis Rubiales hit with restraining order, must avoid player he kissed

MADRID — Luis Rubiales, the former president of the Spanish soccer federation,…

Walmart Investigated in Early 2020 Complaints About Shooter

WSJ News Exclusive Business Employees says regional executives interviewed them about complaints…

Biden administration supports waiving patent protections for Covid vaccines in bid to raise global production

WASHINGTON — The Biden administration said Wednesday they would support waiving patent…